A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 24, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Lenvatinib

8mg (body weight \< 60kg), or 12mg (body weight ≥60kg), QD.

Trial Locations (1)

RECRUITING

Zhongshan Hospital Fudan University, Shanghai

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT06986785 - A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter